Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Sonoma Pharmaceuticals (SNOA) Liabilities from Discontinued Operations (2020)

Sonoma Pharmaceuticals has reported Liabilities from Discontinued Operations over the past 2 years, most recently at 646000.0 for Q1 2020.

For Q1 2020, Liabilities from Discontinued Operations changed N/A year-over-year to 646000.0; the TTM value through Mar 2020 reached 646000.0, changed N/A, while the annual FY2020 figure was 646000.0, N/A changed from the prior year.
Liabilities from Discontinued Operations for Q1 2020 was 646000.0 at Sonoma Pharmaceuticals, up from 112000.0 in the prior quarter.
Over five years, Liabilities from Discontinued Operations peaked at 646000.0 in Q1 2020 and troughed at 112000.0 in Q1 2016.